R Mehta

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. doi request reprint Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects
    Rashmi Mehta
    Clinical Pharmacology Modeling Simulation, GSK, 5 Moore Drive, Research Triangle Park, NC, 27709, USA
    J Pharmacokinet Pharmacodyn 43:153-64. 2016
  2. doi request reprint Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler
    Rashmi Mehta
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Clin Drug Investig 35:319-26. 2015
  3. doi request reprint Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler
    Rashmi Mehta
    GlaxoSmithKline, Research Triangle Park, NC, USA Electronic address
    Pulm Pharmacol Ther 29:66-73. 2014
  4. pmc Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study
    Alison Church
    Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Stevenage SG1 2NY, UK
    BMC Pulm Med 14:2. 2014
  5. doi request reprint Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study
    Rashmi Mehta
    GlaxoSmithKline, Research Triangle Park, North Carolina Electronic address
    Clin Ther 36:1016-1027.e2. 2014
  6. pmc Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
    Rashmi Mehta
    Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 8:159-67. 2013
  7. pmc Bioavailability of inhaled fluticasone propionate via chambers/masks in young children
    K Blake
    Center for Pharmacogenomics and Translational Research, Dept of Biomedical Research, Nemours Children s Clinic, Jacksonville, FL, USA
    Eur Respir J 39:97-103. 2012

Collaborators

Detail Information

Publications7

  1. doi request reprint Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects
    Rashmi Mehta
    Clinical Pharmacology Modeling Simulation, GSK, 5 Moore Drive, Research Triangle Park, NC, 27709, USA
    J Pharmacokinet Pharmacodyn 43:153-64. 2016
    ..These model-predicted results support those of previously-published traditional statistical analyses. ..
  2. doi request reprint Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler
    Rashmi Mehta
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Clin Drug Investig 35:319-26. 2015
    ..The aim of this study was to compare the systemic exposure of SFC 50/100 µg following delivery via the Rotacaps(®)/Rotahaler(®) and the Diskus(®)...
  3. doi request reprint Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler
    Rashmi Mehta
    GlaxoSmithKline, Research Triangle Park, NC, USA Electronic address
    Pulm Pharmacol Ther 29:66-73. 2014
    ....
  4. pmc Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study
    Alison Church
    Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Stevenage SG1 2NY, UK
    BMC Pulm Med 14:2. 2014
    ..Umeclidinium bromide (UMEC) is an inhaled long-acting muscarinic antagonist in development for chronic obstructive pulmonary disease (COPD)...
  5. doi request reprint Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study
    Rashmi Mehta
    GlaxoSmithKline, Research Triangle Park, North Carolina Electronic address
    Clin Ther 36:1016-1027.e2. 2014
    ..Preclinical and clinical data suggest that UMEC and VI are predominantly eliminated by the liver...
  6. pmc Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
    Rashmi Mehta
    Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 8:159-67. 2013
    ....
  7. pmc Bioavailability of inhaled fluticasone propionate via chambers/masks in young children
    K Blake
    Center for Pharmacogenomics and Translational Research, Dept of Biomedical Research, Nemours Children s Clinic, Jacksonville, FL, USA
    Eur Respir J 39:97-103. 2012
    ..VHCs are not interchangeable, as differences in drug delivery to the lung may occur. A population pharmacokinetic approach can be used to determine lung bioavailability of FP...